User:Daniel Schemenauer/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 13: | Line 13: | ||
== Clinical Relevance == | == Clinical Relevance == | ||
| + | ===Role in Diseases=== | ||
| + | |||
| + | ===Interactions with a Negative Allosteric Modulator=== | ||
<scene name='72/726404/Scene_7/2'>Mavoglurant</scene> | <scene name='72/726404/Scene_7/2'>Mavoglurant</scene> | ||
<scene name='72/726409/Mavoglurant_overview/1'>Mavoglurant Stabilzed by ECL2</scene> | <scene name='72/726409/Mavoglurant_overview/1'>Mavoglurant Stabilzed by ECL2</scene> | ||
Revision as of 15:16, 28 March 2016
| |||||||||||
References
- ↑ Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4903-8. Epub 2003 Apr 4. PMID:12679517 doi:http://dx.doi.org/10.1073/pnas.0230374100
- ↑ 2.0 2.1 Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature. 2013 Feb 14;494(7436):185-94. doi: 10.1038/nature11896. PMID:23407534 doi:http://dx.doi.org/10.1038/nature11896
- ↑ Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther. 2003 Jun;98(3):325-54. PMID:12782243
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Dore AS, Okrasa K, Patel JC, Serrano-Vega M, Bennett K, Cooke RM, Errey JC, Jazayeri A, Khan S, Tehan B, Weir M, Wiggin GR, Marshall FH. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature. 2014 Jul 31;511(7511):557-62. doi: 10.1038/nature13396. Epub 2014 Jul 6. PMID:25042998 doi:http://dx.doi.org/10.1038/nature13396
